Annual EBITDA
-$141.71 M
-$87.95 M-163.63%
December 31, 2024
Summary
- As of March 6, 2025, MLTX annual EBITDA is -$141.71 million, with the most recent change of -$87.95 million (-163.63%) on December 31, 2024.
- MLTX annual EBITDA is now -163.63% below its all-time high of -$53.75 million, reached on December 31, 2023.
Performance
MLTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$48.28 M
-$5.20 M-12.07%
December 31, 2024
Summary
- As of March 6, 2025, MLTX quarterly EBITDA is -$48.28 million, with the most recent change of -$5.20 million (-12.07%) on December 31, 2024.
- Over the past year, MLTX quarterly EBITDA has dropped by -$5.20 million (-12.07%).
- MLTX quarterly EBITDA is now -670.63% below its all-time high of -$6.26 million, reached on September 30, 2021.
Performance
MLTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$141.71 M
-$33.61 M-31.09%
December 31, 2024
Summary
- As of March 6, 2025, MLTX TTM EBITDA is -$141.71 million, with the most recent change of -$33.61 million (-31.09%) on December 31, 2024.
- Over the past year, MLTX TTM EBITDA has dropped by -$33.61 million (-31.09%).
- MLTX TTM EBITDA is now -333.59% below its all-time high of -$32.68 million, reached on June 30, 2021.
Performance
MLTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
MLTX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -163.6% | -12.1% | -31.1% |
| 3 y3 years | - | -273.4% | -129.0% |
| 5 y5 years | - | -273.4% | -129.0% |
MLTX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -163.6% | at low | -273.4% | at low | -255.6% | at low |
| 5 y | 5-year | -163.6% | at low | -670.6% | at low | -333.6% | at low |
| alltime | all time | -163.6% | at low | -670.6% | at low | -333.6% | at low |
MoonLake Immunotherapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$141.71 M(+163.6%) | -$48.28 M(+12.1%) | -$141.71 M(+31.1%) |
| Sep 2024 | - | -$43.08 M(+41.0%) | -$108.10 M(+38.6%) |
| Jun 2024 | - | -$30.55 M(+54.3%) | -$77.99 M(+28.6%) |
| Mar 2024 | - | -$19.80 M(+35.0%) | -$60.62 M(+12.8%) |
| Dec 2023 | -$53.75 M | -$14.67 M(+13.1%) | -$53.75 M(-3.4%) |
| Sep 2023 | - | -$12.97 M(-1.6%) | -$55.63 M(-3.1%) |
| Jun 2023 | - | -$13.18 M(+2.0%) | -$57.42 M(-7.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | -$12.93 M(-21.8%) | -$61.89 M(-4.6%) |
| Dec 2022 | -$64.90 M | -$16.54 M(+12.0%) | -$64.90 M(+34.2%) |
| Sep 2022 | - | -$14.77 M(-16.3%) | -$48.36 M(+21.3%) |
| Jun 2022 | - | -$17.65 M(+10.7%) | -$39.85 M(-27.4%) |
| Mar 2022 | - | -$15.94 M(+154.4%) | -$54.89 M(+40.9%) |
| Sep 2021 | - | -$6.26 M(-80.8%) | -$38.95 M(+19.2%) |
| Jun 2021 | - | -$32.68 M | -$32.68 M |
FAQ
- What is MoonLake Immunotherapeutics annual EBITDA?
- What is the all time high annual EBITDA for MoonLake Immunotherapeutics?
- What is MoonLake Immunotherapeutics annual EBITDA year-on-year change?
- What is MoonLake Immunotherapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for MoonLake Immunotherapeutics?
- What is MoonLake Immunotherapeutics quarterly EBITDA year-on-year change?
- What is MoonLake Immunotherapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for MoonLake Immunotherapeutics?
- What is MoonLake Immunotherapeutics TTM EBITDA year-on-year change?
What is MoonLake Immunotherapeutics annual EBITDA?
The current annual EBITDA of MLTX is -$141.71 M
What is the all time high annual EBITDA for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics all-time high annual EBITDA is -$53.75 M
What is MoonLake Immunotherapeutics annual EBITDA year-on-year change?
Over the past year, MLTX annual EBITDA has changed by -$87.95 M (-163.63%)
What is MoonLake Immunotherapeutics quarterly EBITDA?
The current quarterly EBITDA of MLTX is -$48.28 M
What is the all time high quarterly EBITDA for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics all-time high quarterly EBITDA is -$6.26 M
What is MoonLake Immunotherapeutics quarterly EBITDA year-on-year change?
Over the past year, MLTX quarterly EBITDA has changed by -$5.20 M (-12.07%)
What is MoonLake Immunotherapeutics TTM EBITDA?
The current TTM EBITDA of MLTX is -$141.71 M
What is the all time high TTM EBITDA for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics all-time high TTM EBITDA is -$32.68 M
What is MoonLake Immunotherapeutics TTM EBITDA year-on-year change?
Over the past year, MLTX TTM EBITDA has changed by -$33.61 M (-31.09%)